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Apoptosis and inflammation, important contributors to the
progression of chronic kidney disease, can be influenced
by clusterin (a secreted glycoprotein that regulates
apoptosis) and nuclear factor-jB (NF-jB, a transcription
factor modifying the expression of inflammatory genes).
We studied proteinuria-induced renal disease and its
influence on clusterin-mediated apoptosis. Exposure of
cultured mouse proximal tubule epithelial cells to bovine
serum albumin (BSA) resulted in activation of NF-jB and
activator protein-1 (AP-1) within hours followed by a decline
in their activation, decreased activation of extracellular
signal-regulated kinases (ERK1/2), decreased cell-associated
antiapoptotic Bcl-xL protein but increased apoptosis.
Clusterin progressively increased in the media over a
3 day period. Clusterin siRNA blocked protein production,
increased NF-jB activation, and significantly increased
cellular Bcl-xL protein, thereby reducing spontaneous and
BSA-induced apoptosis. An siRNA to the NF-jB inhibitor
IjBa had similar results. BSA-stimulated NF-jB activation
reciprocally decreased AP-1 activity by preventing ERK1/2
phosphorylation. These in vitro studies suggest that clusterin
inhibits NF-jB-mediated antiapoptotic effects by the
apparent stabilization of IjBa switching from promoting
inflammation to apoptosis during proteinuria.
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Clusterin is a secreted heterodimeric glycoprotein with a
diversity of functions, as evidenced by its many aliases,
including apolipoprotein J and SP-40,40; overall, the exact
biological roles for clusterin remain uncertain.1–4 Perhaps, the
best illustration of the diverse and at times contradictory
functions of clusterin is its role in apoptosis. On the one
hand, clusterin has been reported to track with surviving
cells in tissue regressing as a consequence of apoptosis5 and
to prevent apoptosis induced by tumor necrosis factor-a
(TNF-a).6,7 Conversely, clusterin induces apoptosis in both
malignant and nonmalignant prostatic epithelial cells,8 after
ionizing radiation,9 and in hypoxia–ischemia-induced brain
damage, the latter shown in mice with targeted deficiency of
clusterin.1 Clusterin is induced in injured organs such as in
Alzheimer’s disease,10 myocardial infarction,11 cancer,2 and
various renal diseases.12 In the case of renal diseases, particu-
larly when there is substantial proteinuria, clusterin is synthe-
sized by damaged tubular cells and subsequently secreted into
the urine.13,14 Tubular cell clusterin also has the potential to
be cytoprotective.15 Although the regulatory influences on
clusterin gene expression in the kidney are unknown, in other
systems, clusterin expression can be stimulated by activator
protein-1 (AP-1), c-fos, and extracellular signal-regulated
kinase (ERK1/2) signal transduction cascades.16–18
Nuclear factor-kB (NF-kB) is a key transcription factor that
upon activation in the cytosol, translocates to the nucleus and
leads to the transcription of a variety of proinflammatory
genes. Interestingly, NF-kB is also a regulator of apoptosis, in
that it inhibits TNF-a-induced apoptosis.19–21 Yet, it is still not
clear how NF-kB and its various transcriptional actions impact
apoptosis. Similar to clusterin, the role of NF-kB in the kidney
and its disease states is not uniform. For instance, as in other
cells like fibroblasts,19,21 NF-kB protects mesangial cells from
TNF-a-induced apoptosis.22,23 In contrast, oxidative stress
increases NF-kB activity and apoptosis in the renal tubuloin-
terstitium (TI) in experimental hypertension24 and blocking
NF-kB activation inhibits ischemia-induced renal tubular cell
apoptosis.25 Clearly, NF-kB is a stress response factor in
inflammation that can control whether a cell lives or dies.20
Arguably, the most important factor in renal disease of any
kind is the state of the tubulointerstitium – more so than the
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features of glomerular disease, even in primary glomerular
diseases.26,27 In studies in vivo, tubulointerstitium injury has
been shown to occur from NF-kB activation28,29 and induction
of apoptosis30 in bovine serum albumin (BSA)-overloaded
proteinuric rats. In in vitro studies, various manipulations of
proximal tubular epithelial cells (PTECs) induce apoptosis, such
as exposure to TNF-a,31 lipopolysaccharide,32 or BSA.33 Overall,
the relevance of BSA exposure to PTECs is well suited to study
inflammation and apoptosis in progressive renal disease.
Our previous studies have shown a role for NF-kB in renal
tubulointerstitium injury in BSA-overloaded rats with heavy
native and exogenous albuminuria.29,34 In follow-up studies
from this model, we found that clusterin production by
PTECs was significantly increased in the BSA-overloaded rats
and further increased by inhibition of NF-kB. Relating to
NF-kB and clusterin is a recent study showing a physiological
role for clusterin in inhibiting NF-kB signaling through
stabilization of the inhibitor of NF-kB a (IkBa).35 To better
understand the mechanisms of inflammation and apoptosis
in progressive renal disease, here we focused on both NF-kB,
as a central mediator of inflammation, and clusterin, as a
regulator of apoptosis in PTECs exposed to BSA.
RESULTS
BSA-induced apoptosis
BSA has been shown to induce apoptosis in other PTEC
culture systems.33 In these studies, cultured mouse PTECs
were incubated with various concentrations of BSA for 72 h,
following which apoptosis was determined with a single-
stranded (ss) DNA enzyme-linked immunosorbent assay.
Given the potential for variability among different sources
of BSA, two preparations from different vendors were studied
in parallel. In addition, because of the utilization of small
interference RNA (siRNA) in subsequent experiments, cells
were studied with or without control siRNA treatment to
exclude any independent effect of siRNA on apoptosis. Expo-
sure of PTECs to concentrations of BSAX2.5 mg ml1 led to
significant apoptosis, which was not affected to a significant
extent by the source of BSA or the presence of siRNA (Figure
1a). In addition to increased ssDNA quantities, PTECs
exposed to BSA also exhibited morphological features
consistent with apoptosis, including nuclear condensation
and fragmentation, which were similarly unaffected by the
source of BSA or the presence of control siRNA (Figure 1b).
Quantification of apoptosis visualized with Hoechst staining
showed that after 72 h, 1.570.1% of adherent cells were
apoptotic in buffer alone, whereas 7.570.9, 6.570.8, and
7.770.6% of adherent cells were apoptotic after exposure to
5 mg ml BSA1 (no. 1 with or without control siRNA, and
no. 2, respectively). Based on these studies, in all subsequent
experiments, we exposed PTECs to a single BSA preparation
(no. 2 in Figure 1a) at a concentration of 5 mg ml1, given
that two- or threefold higher concentrations did not consi-
derably increase apoptosis in PTECs. In addition, this lower
concentration has greater relevance to conditions in vivo
(discussed below).
Effects of PTEC clusterin, IjBa, and NF-jB p65 on BSA-
induced apoptosis
We focused on NF-kB as a central mediator of inflammation,
IkBa as an inhibitor of NF-kB, and clusterin as a regulator
of apoptosis. Each had a unique pattern of expression over
time following exposure to BSA (Figure 2). Control PTECs
secreted clusterin into the medium; exposure to BSA accele-
rated this both in time and magnitude, leading to approxi-
mately two-fold greater quantities of clusterin at the 48 and
72 h time points. Relative to controls, cytoplasmic expression
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Figure 1 | BSA induces dose-dependent apoptosis in PTECs. PTECs
were exposed to control siRNA or buffer alone followed by
incubation for 72 h in various concentrations of BSA from two
separate sources (no. 1 from GIBCO BRL, no. 2 from Sigma-Aldrich).
(a) The cumulative generation of ssDNA by apoptotic cells was
measured by enzyme-linked immunosorbent assay. Values are
expressed as ratios relative to controls not exposed to BSA and
presented as means7s.e.m. from 3 to 4 individual experiments. Cells
were pretreated with buffer (&) or control siRNA (’). *Po0.05 vs
buffer (0 mg ml1 BSA)þ control siRNA. (b) Morphological
appearance of apoptosis was determined by nuclear staining with
(b) Hoechst 33258 after 72 h exposure to buffer alone or (c–e)
5 mg ml1 BSA from either source, (d) in the presence or (c and d)
absence of control siRNA. Nuclear fragmentation characteristic of
apoptosis is apparent in cells exposed to BSA, with no difference
seen with the different sources or the presence of siRNA. Original
magnification,  200.
568 Kidney International (2008) 73, 567–577
o r i g i n a l a r t i c l e O Takase et al.: Clusterin prevents NF-jB-dependent Bcl-xL production
and then was increased from 1 to 10 h presumably as a conse-
quence of its re-synthesis. At later time points (48–72 h), it
was decreased again relative to controls. The expression of
NF-kB p65 in the cytoplasm of PTECs exposed to BSA
tended to be increased relative to controls at early time
points, although this was not statistically different; thereafter,
there was no difference between the two cellular preparations.
To determine the interrelationships between clusterin,
IkBa, and NF-kB p65 in PTECs exposed to BSA, an siRNA
approach was used to inhibit these target genes. As before,
exposure of PTECs to 5 mg ml1 BSA for 72 h led to
increased protein expression of clusterin in supernatants
and a decrease in cytoplasmic IkBa (Figure 3). Furthermore,
as expected, the expression of clusterin, IkBa, and NF-kB
p65 proteins in PTECs 72 h after exposure to 5 mg ml1 BSA
was decreased by their respective siRNAs. The expression
of clusterin and IkBa was also significantly inhibited by each
other’s siRNA, and increased by NF-kB p65 siRNA relative to
BSA-only controls. Conversely, the expression of NF-kB p65
was significantly increased by both clusterin and IkBa siRNA.
The potential relevance of clusterin, IkBa, and NF-kB p65
to apoptosis in PTECs exposed to 5 mg ml1 BSA was investi-
gated. In addition, the time course of apoptosis was also
evaluated in these sets of studies. Relative to time zero
controls, PTECs in medium alone had increased ssDNA at all
subsequent time points (Figure 4). This was significantly
increased by exposure to 5 mg ml1 BSA for 72 h, which
was associated with morphological evidence for apoptosis
(cf, Figure 1b). This BSA-dependent apoptosis was blocked
with clusterin siRNA, and was promoted further by NF-kB
p65 siRNA (Figure 4). Similar effects as clusterin siRNA were
seen with IkBa siRNA (data not shown).
Activation of NF-jB and AP-1 in PTECs exposed to BSA
Given the potential of activated transcription factors NF-kB
and AP-1 to influence subsequent events in PTECs incubated
in BSA, these were next examined. Exposure to BSA led to
NF-kB and AP-1 activation, which was maximal between
5 and 24 h but persisted up to 72 h relative to controls not



















































0 0.5 1 3 5 10 24 48 72
0 0.5 1 3 5 10 24 48 72






















5 mg ml–1 BSA
0 mg ml–1 BSA 
Figure 2 | Expression of clusterin, IjBa, and NF-jB p65 proteins in PTECs exposed to BSA. PTECs were incubated in buffer or 5 mg ml1
BSA for various times. The expression of clusterin in the medium and that of IkBa and NF-kB p65 in the cytoplasm were detected by western
blotting. Relative expression levels over time determined by densitometry are shown in the adjacent plots as means7s.e.m. from 3 to 4
individual experiments. *Po0.05 vs buffer alone (0 mg ml1 BSA) at the same time.
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and NF-kB p65 gene knockdowns on NF-kB and AP-1
activation in PTECs 5 and 72 h after exposure to BSA were
evaluated. There was marked NF-kB and AP-1 activation with
5 h exposure to BSA (Figure 5b). At this time, knock-
down of clusterin or IkBa led to a modest increase in NF-kB
activation and nearly completely prevented activation of AP-1,
whereas NF-kB p65 siRNA blocked NF-kB but not AP-1
activation. At 72 h following incubation in BSA, the magni-
tude of both NF-kB and AP-1 activation by BSA was less than
that at 5 h (Figure 5c), with the effects of clusterin, IkBa, and
NF-kB p65 siRNA similar to those at 5 h. The specificity
of each oligonucleotide was confirmed in control studies
in which NF-kB and AP-1 complexes were abolished by an
excess of unlabeled consensus oligonucleotides, but not by
mutant oligonucleotides (data not shown). Overall, these
results show activation of both NF-kB and AP-1 by BSA, with
NF-kB capable of being activated further when the produc-
tion of clusterin or IkBa was inhibited, in which setting AP-1
activation was blocked. In contrast, AP-1 activation appeared
to be maximal, with no further increase apparent by blocking
NF-kB p65 activation.
Effect of BSA on mitogen-activated protein kinase activation
in PTECs exposed to BSA
Clusterin, NF-kB, and AP-1 are known to be interrelated, as
shown above in PTECs exposed to BSA. As potential inter-
mediates relevant to PTECs exposed to BSA, as well as to
clusterin expression and AP-1 activation, the mitogen-activated
protein kinases, ERK, phospho-c-Jun NH2-terminal kinase
(JNK), and p38 were evaluated.17,36,37 The activation of JNK
and p38 was weak to absent with no effect of time and or BSA
dose up to 15 mg ml1 (data not shown). Phosphorylation of
ERK1/2 in control PTECs was evident within 24 h, and increased
at later times up to 72 h (Figure 6a and b), as is known to occur
in PTECs under comparable conditions.38 In contrast, phospho-
ERK1/2 was transiently increased within 5 min of exposure to
BSA, but then remained relatively inactivated at later time points
(48 and 72 h). Inhibition of clusterin, IkBa, and NF-kB p65 with
siRNA had no effect on the early ERK1/2 activation, whereas the
reduced ERK1/2 activation brought about by BSA after 72 h was
modestly but not significantly decreased by clusterin and IkBa
siRNA, and increased above control levels with NF-kB p65
siRNA (Figure 6c).
Effect of BSA on PTEC Bcl-xL, Bax, and cytochrome c
The expression of the apoptotic-associated proteins Bax and
Bcl-xL is known to be dependent on NF-kB activation.39,40 In
control PTECs not exposed to BSA, there was an increase
in Bcl-xL protein over time; in contrast, PTECs exposed to
5 mg ml1 BSA exhibited a gradual decline in Bcl-xL (Figure
7a). This decrease was clearly affected by clusterin, as its
inhibition led to a marked increase in Bcl-xL above both
control and BSA-exposed PTECs studied at 24, 48, and 72 h
time points (Figure 7b). In particular, the production of
Bcl-xL was increased B3 times the basal level by inhibition
of clusterin and IkBa in PTECs exposed to BSA for 72 h
(Figure 7c). In these experiments, blockade of NF-kB p65 did
inhibit spontaneous Bcl-xL production at 72 h, which was
also true for BSA-stimulated cells, although this was not
statistically different (Figure 7b and c). In no experimental
condition was Bax protein altered (Figure 7c). Furthermore,
the expression of cytoplasmic cytochrome c, as a marker for
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Figure 3 | Effect of gene knockdown on clusterin, IjBa, and NF-jB
p65 protein expression in PTECs exposed to BSA. PTECs were
treated with clusterin, IkBa, or NF-kB p65 siRNA before exposure
to 5 mg ml1 BSA for 72 h. Expression of clusterin in the medium,
and that of IkBa, NF-kB p65, and a-tubulin in the cytoplasm at 72 h
were detected by western blotting. All samples for a given
experiment were electrophoresed in the same gel. Values obtained
by densitometry were normalized to a-tubulin and expressed as
ratios relative to controls not exposed to BSA and presented as
means7s.e.m. from 3 to 9 individual experiments. *Po0.05 vs
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Figure 4 | Effect of gene knockdown on BSA-induced apoptosis
over time. PTECs were treated with indicated siRNAs and then
exposed to 5 mg ml1 BSA or buffer alone (0 mg ml1 BSA) for the
indicated times. Apoptosis was measured by ssDNA enzyme-linked
immunosorbent assay with data expressed relative to the time
zero control for each experimental condition. Data are means7s.e.m.
of 4–8 experiments. *Po0.05 vs cells exposed to buffer alone
(0 mg ml1 BSA), #Po0.05 vs 5 mg ml1 BSA (no siRNA), wPo0.05 vs
5 mg ml1 BSAþ clusterin siRNA.
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PTECs, which was significantly decreased with clusterin and
IkBa siRNA treatment (Figure 7c).
Effects of BSA overload in vivo
In mice with protein overload, there was increased urinary
albumin of both murine and bovine origin (data not shown).
In these kidneys, there was focal expression of clusterin in
both glomeruli and in tubules, which increased in distribu-
tion and intensity from 1 to 3 weeks of disease (Figure 8a).
There was also prominent PTEC apoptosis (see below)
and expression of heat-shock protein 47 as a marker for
collagen I production and presumed epithelial–mesenchymal
transition41 (green in Figure 8b); yet, there was no increased
pool of interstitial fibroblasts (red in Figure 8b), supporting
that the pathological effects of albumin remained limited to
the PTECs up to 3 weeks of disease. At this time, there were
many tubular cell segments with widespread cellular
apoptosis in which the remaining ‘viable’ cells consistently
expressed clusterin (Figure 8c). These data provide circum-
stantial evidence supporting our in vitro studies that clusterin
is proapoptotic in PTECs exposed to excessive quantities
of albumin.
DISCUSSION
Here we have used cultured mouse PTECs exposed to BSA as
a model reflective of events occurring in proteinuric states. In
this system, we have confirmed previous reports that ERK1/2,
NF-kB, and AP-1 are activated early after incubation in
BSA and that apoptosis follows.42–44 However, the later time
course, which is relevant to inflammation and apoptosis, was
also informative (Figure 9). NF-kB and AP-1 remained
activated up to 72 h after BSA exposure, whereas ERK1/2
activation was relatively inhibited in these conditions. As an
explanation for the resultant apoptosis, we have shown a
progressive decline in the potent antiapoptotic protein Bcl-xL
and increased release of mitochondrial cytochrome c. We also
show for the first time that clusterin secretion is induced in
PTECs within hours, and this progressively accumulates over
time up to 72 h.
To determine the interrelationship between clusterin and
the NF-kB system, we used an siRNA approach to block
clusterin, IkBa, and NF-kB p65 protein production. In all of
the processes studied – activation of ERK, AP-1 and NF-kB,
production of Bcl-xL, and induction of apoptosis – inhibition
of clusterin and IkBa acted in the same direction typically in
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Figure 5 | NF-jB and AP-1 activation in PTECs exposed to BSA. Representative electrophoretic mobility shift assay autoradiograms are
shown revealing NF-kB- and AP-1-binding activity in PTEC nuclear proteins obtained at various times following exposure to 5 mg ml1 BSA.
(a) Time course from 0 to 72 h. Effect of gene knockdown on NF-kB and AP-1 activation (b) 5 and (c) 72 h after exposure to BSA. Densitometric
data for NF-kB activation relative to controls at 72 h are presented as means7s.e.m. of three experiments. *Po0.05 vs 0 BSA/siRNA,
#Po0.05 vs 5 mg/ml BSA/siRNA, wPo0.05 vs 5 mg ml1 BSAþ clusterin siRNA, zPo0.05 vs 5 mg ml1 BSAþ IkBa siRNA.
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an equivalent magnitude, whereas inhibition of NF-kB p65
acted in the opposite direction. An explanation for this is
apparent by examining the fate of cytoplasmic IkBa when
clusterin production was prevented. In this case, IkBa was
absent, suggesting that clusterin blocks IkBa degradation,
thereby preventing NF-kB translocation to the nucleus
and its transcriptional effects, including production of Bcl-
xL, which can protect from apoptosis.
There is extensive crosstalk apparent between ERK, AP-1,
and NF-kB systems. Presumably, the early ERK activation
in response to BSA occurring within minutes proceeds
independently from NF-kB and AP-1 activation. That this is
the case was shown directly in experiments with IkBa and
NF-kB p65 siRNA. Studies in mouse and human PTECs
exposed to BSA have shown a nearly identical early response,
which was shown in the latter to be due to epidermal growth
factor receptor activation by BSA.45 Yet, at later time points,
ERK1/2 activation was relatively inhibited in PTECs exposed
to BSA compared to control PTECs. The explanation for
this is apparent in studies in which NF-kB p65 was blocked,
wherein ERK1/2 activation was considerably increased. That
this was greater than levels occurring spontaneously suggests
that products of NF-kB p65 have an intrinsic inhibitory effect
on ERK1/2 phosphorylation, which is magnified by exposure
to BSA.
The effects of ERK and AP-1 on apoptosis are complex
and at times contradictory. The activities of AP-1 are being
elucidated over time, which include a connection with
NF-kB and the ability to profoundly influence cellular
survival and apoptosis.46 In our studies, we have shown that
AP-1 is activated in cells exposed to BSA, which cannot be
enhanced by blockade of NF-kB, suggesting that it is already
maximally stimulated. Yet, it can be completely blocked by
inhibition of clusterin or IkBa, illustrating that AP-1
activation can be inhibited by products of NF-kB. Support
for this contention comes from the immune response,
in which TNF-a-stimulated NF-kB activation results in
inhibition of JNK, thereby preventing c-Jun/AP-1 activa-
tion and providing protection from apoptosis.47 Similar
findings that JNK/AP-1 is proapoptotic and under negative
feedback control from NF-kB have recently been reported
in dendritic cells.47 Consistent with previous studies are our
results of only weak JNK activity unchanged in response
to BSA.42
In our studies, the increased appearance of pERK1/2
in control cells was associated with less apoptosis. Yet, by
increasing ERK1/2 activation when NF-kB was inhibited,
there was marked ERK1/2 activation in BSA-exposed PTECs,
which was associated with substantially greater apoptosis.
This is consistent with the findings that ERK activation
can be directly responsible for apoptosis in PTECs.38 Given
the role for ERK1/2 in AP-1 activation,48,49 this suggests a
direct link between the two, which is also supported by our
data. In addition, the relative state of ERK1/2 and AP-1
activation correlated with apoptosis. The link between AP-1
and ERK1/2 activation and apoptosis in PTECs may involve
clusterin expression, which is known to promote apoptosis in
other cells.2,8,50 Notably, in cancer cells, clusterin can inhibit
apoptosis,51 which has been attributed to its interaction with
activated Bax;52 in our system, there was no change in Bax
with any manipulation, arguing against any role for this type
of response. Yet, the potent antiapoptotic protein Bcl-xL
was decreased and mitochondrial cytochrome c release was
increased in response to BSA and correlated with apoptosis.
Furthermore, when clusterin was inhibited, Bcl-xL expression
was markedly increased in an NF-kB-dependent manner,
which was associated with decreased cytochrome c appear-
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Figure 6 | ERK activation in PTECs. PTECs were incubated with 0
or 5 mg ml1 BSA for various times. (a) Phosphorylation of ERK1/2 in
the cytoplasm was detected by western blotting. (b) Values for
phospho-ERK1/2 obtained by densitometry from 3 to 4 experiments
were normalized to those for total ERK2 and expressed as ratios
relative to values of the control group not exposed to BSA. *Po0.05
vs buffer alone (0 mg ml1 BSA). (c) Effect of gene knockdown on
ERK1/2 activation. PTECs were exposed to clusterin, IkBa, or NF-kB
p65 siRNA before incubation in 0 or 5 mg ml1 BSA for 5 min
(n¼ 2) or 72 h (n¼ 3) followed by detection of phospho-ERK1/2 and
total ERK2 by western blotting. Values for phospho-ERK1/2 obtained
by densitometry were normalized to those for total ERK2 and
expressed as ratios relative to values of the control group not
exposed to BSA. *Po0.05 vs buffer alone (0 mg ml1 BSA),
#Po0.05 vs 5 mg ml1 BSA.
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ance in the cytoplasm and protection from apoptosis. The
plausible explanation from our data is that activated ERK1/2
and/or AP-1 lead to clusterin production and protection of
IkBa from degradation, preventing NF-kB from producing
Bcl-xL to protect against apoptosis.
It seems likely that in our system, clusterin functions in a
paracrine manner in that newly synthesized clusterin is
secreted into the culture supernatant (as a surrogate for the
tubular lumen) and is taken up and delivered to cytosolic
sites where it can act as a chaperone to prevent IkB kinase-
mediated phosphorylation, ubiquitination, and degradation
of the NF-kB inhibitor IkBa. This can account for the
effects of clusterin to block NF-kB activity,35 including its
antiapoptotic actions.19 PTECs are heavily endowed with the
endocytic protein megalin, as is true of the cells we used in
these studies (data not shown), which is capable of shuttl-
ing clusterin to cytoplasmic sites.53 Of note is that other
pathways for clusterin uptake can also be operative, such as
that observed in a porcine PTEC line.15
The normal glomerulus is efficient at restricting plasma
proteins from entering the more than 100 l of ultrafiltrate
formed daily in humans.54,55 When the glomerulus is
diseased, this barrier is abnormal and plasma proteins
appear in the glomerular ultrafiltrate. The sieving coefficient
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5






1.0 0.5±0.1∗ 2.9±1.0∗# 3.4±0.9∗# 0.5±0.1∗
(mg ml–1)


































Clusterin NF-κBp65 Clusterin− NF-κBp65−
24 h
48 h
1.0 1.43±0.03∗ 0.99±0.03† 0.97±0.05† 1.46±0.02∗# 0.95±0.08†
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Figure 7 | Appearance of Bcl-xL, Bax, and cytochrome c in PTECs. PTECs were incubated with 0 or 5 mg ml1 BSA for various times.
The appearance of Bcl-xL protein in the cytoplasm was detected by western blotting (a) with the time course derived from densitometry from
3 to 4 independent experiments shown in the adjacent graph. *Po0.05 vs buffer alone (0 mg ml1 BSA). (b and c) Effect of gene knockdown
on Bcl-xL and Bax. PTECs were exposed to clusterin, IkBa, or NF-kB p65 siRNA before incubation in 0 or 5 mg ml1 BSA for 72 h (n¼ 3–5)
followed by detection of Bax, Bcl-xL, cytochrome c, and a-tubulin by western blotting. Values for Bax, Bcl-xL, and cytochrome c obtained by
densitometry were normalized to those for a-tubulin and expressed as ratios relative to values of the control group not exposed to BSA.
*Po0.05 vs buffer alone (0 mg ml1 BSA), #Po0.05 vs 5 mg ml1 BSA, wPo0.05 vs 0 or 5 mg ml1 BSAþ clusterin siRNA.
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(Y¼ concentration of a given molecule in Bowman’s space
divided by its concentration in plasma) has been modeled
and directly studied with micropuncture studies in rats and
through the use of exogenous polymers that are not affected
by tubules in animals and humans. In patients with nephrotic
syndrome, Yalbumin increases to B0.01, which approximates
that of an equivalently sized neutral polymer reflecting loss of
charge selectivity.54 Under such conditions, 10% of plasma
albumin will appear in Bowman’s space at any given time;
assuming a plasma albumin concentration of 40 mg ml1,
this would be 4 mg ml1 leading to B600 g filtered daily
(150 l day1 4000 mg l1) with tubular uptake of albumin
accounting for the difference between this amount and the
relatively small amount of albumin that ultimately appears in
the urine (typically o20 g day1). Hence, there is a clear
relevance to proteinuric diseases by examining events in
PTECs exposed to albumin.
In summary, here we have shown a clear sequence of
events occurring after PTECs are exposed to concentrations
of BSA likely to occur in disease states in vivo. Activation of
ERK1/2 and IkBa degradation are followed soon thereafter
by AP-1 and NF-kB activation and their subsequent trans-
criptional events. Initially, NF-kB predominates, which in
aggregate is pro-inflammatory but antiapoptotic, the latter, at
least in part, through production of Bcl-xL. Another product
induced by BSA is clusterin, possibly through ERK1/2 and/or
AP-1, which by virtue of its stabilizing effects on IkBa
prevents continued NF-kB activation. This allows the effects
of AP-1 to predominate later after exposure to BSA, includ-
ing the induction of apoptosis. Overall, clusterin prevents
NF-kB from exerting its antiapoptotic effects and may play a
key role in switching from inflammation to apoptosis in
proteinuric conditions. Whether this is true in vivo requires
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Figure 8 | Histological studies of BSA overloaded mouse kidneys. Kidneys from mice with BSA-overload were studied for
(a) expression of clusterin after 1, 2, and 3 weeks, (b) HSP47 (green) and fibroblasts (using monoclonal antibody ER/TR7, red), and

















Figure 9 | Paradigm for events occurring over time in PTECs
exposed to BSA. Exposure of PTECs to BSA leads to acute ERK1/2
and IkBa activation, which results in sustained AP-1 and NF-kB
activation and clusterin production. The likelihood for other
activators of AP-1, NF-kB, and clusterin is denoted by ‘þ ?.’ pERK1/2
stimulates AP-1 activation, with either or both inducing clusterin
production, and the effects of AP-1 and Bcl-xL to promote and inhibit
apoptosis, respectively, are lightly shaded to indicate that they are
supported by prior data, as well as correlative but not direct
experimental data in these studies (see text for details).
574 Kidney International (2008) 73, 567–577
o r i g i n a l a r t i c l e O Takase et al.: Clusterin prevents NF-jB-dependent Bcl-xL production
MATERIALS AND METHODS
Basic experimental protocol in vitro
An established mouse PTEC line was kindly provided by Dr John
Schwartz (Boston University) and shown to be proximal tubular in
origin by a combination of biochemical, morphological, and
transport characteristics.56 PTECs were grown in Dulbecco’s
modified Eagle’s medium (DMEM) (GIBCO BRL, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum, 100 U ml1
penicillin, and 100mg ml1 streptomycin (Cellgro, Kansas City, MO,
USA) at 371C in a 5% CO2/95% O2 environment. Upon reaching
confluence, cells were washed twice with DMEM and subsequently
incubated at 371C for 0–72 h in DMEM with or without fatty acid-
free BSA (AA8806 from Sigma-Aldrich, St Louis, MO, USA or
15260-037 from GIBCO BRL), following which culture supernatants
and cells were harvested for the measurements described below.
BSA overload in mice
A modification of the BSA overload models of Eddy et al.57 and
Egido58 was used, in which escalating daily intraperitoneal doses of
BSA (fatty acid- and endotoxin-free, concentrated to 400 mg ml1)
were administered over 1 week to arrive at a final daily dose of
400 mg per mouse given 6 days per week. All animals developed the
expected native and exogenous albuminuria. Groups of two mice
were killed at weekly intervals, with kidneys evaluated for apoptosis
and expression of clusterin, fibroblasts (monoclonal antibody ER/
TR759), and HSP-47 as a marker for increased collagen synthesis.41
Kidneys were processed and stained using previously described
methods,60,61 which will be briefly described. Immunohistochemical
staining for clusterin (b-chain specific, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was conducted using a Vectastain Elite ABC
kit (Vector Laboratories, Burlingame, CA, USA) with some
modifications. Briefly, portions of renal tissue not more than
2 mm thick were fixed in 4% paraformaldehyde in phosphate-
buffered saline (pH 7.4) for 24 h at 41C. Five micrometer tissue
sections were deparaffinized and hydrated through a descending
series of alcohols. Endogenous peroxidase activity was quenched by
incubation in 3% hydrogen peroxide in Tris-buffered saline (pH
7.4). Epitope retrieval was carried out in sections by microwave
treatment (2 5 min in 100 mM sodium citrate, pH 6). Sections
were sequentially blocked for nonspecific staining (diluted normal
serum, 1:67, 60 min) and endogenous biotin (avidin/biotin blocking
kit, Vector Labs, 30 min per step). Blocking was followed by
incubation with affinity-purified antibody, control IgG, or ‘blocking
peptide’ (1 h at room temperature or overnight at 41C). The sections
were then washed in Tris-buffered saline and incubated with
biotinylated secondary antibody. After further washes with Tris-
buffered saline, the sections were incubated with an avidin–bioti-
nylated horseradish peroxidase complex for 1 h. Finally, the sections
were washed in Tris-buffered saline and color was developed by the
addition of 50 mM sodium phosphate buffer, pH 7.6, containing
0.12% 3,3-diaminobenzidine tetrahydrochloride (Sigma, St Louis,
MO, USA), 0.0075% nickel chloride, 0.0075% cobalt chloride, and
0.0075% hydrogen peroxide for 5–10 min. Tissue sections were
routinely counterstained by Mayer’s hematoxylin. Staining of kidney
tissue from untreated kidney or staining with non-immune serum
or rabbit IgGs was performed for controls. Staining with control
reagents was negative in all cases. All the procedures were carried out
at room temperature unless otherwise noted.
Intra-renal apoptosis was detected with the Trevigen TACS-XL-
Blue Label In situ Apoptosis Detection Kit (Trevigen Inc.,
Gaithersburg, MD, USA). Briefly, 5mm tissue sections adjacent to
those used for clusterin detection were de-waxed in Histoclear and
hydrated through a descending series of alcohols to phosphate-
buffered saline (pH 7.4). Proteinase K (20 mg ml1) treatment was
followed by quenching for endogenous peroxidase activity. The
sections were then incubated with a labeling buffer containing a
brominated nucleotide and terminal deoxynucleotidyl transferase at
371C. The incorporated 5-bromo-20 deoxyuridine was detected by
anti-5-bromo-20 deoxyuridine, followed by streptavidin–horseradish
peroxidase and a proprietary TACS Blue label. Sections were
counterstained using nuclear fast red.
siRNA treatment
Transfection regents and siRNA for clusterin, IkBa, and NF-kB
p65 were obtained from Santa Cruz Biotechnology. Subconfluent
cells were washed twice with DMEM and subsequently grown in
12-well culture dishes containing DMEM and 10% fetal bovine
serum without antibiotics to which a mixture of individual siRNAs
for clusterin, IkBa, or NF-kB p65, transfection medium, and reagent
solution were added. After 30 h, cells were washed and then exposed
to BSA as above.
In pilot studies, to evaluate the transfection efficiency of siRNA
treatment, PTECs were incubated for 30 h with different concentra-
tions of fluorescein-conjugated siRNA (Santa Cruz Biotechnology)
and siRNA expression in PTECs was evaluated by fluorescence
microscopy. By this approach, the efficiency was dose-dependent
with B20, B60, and B80% positive cells at 50, 100, and 150 nM,
respectively. Therefore, in all studies, 150 nM siRNA was used.
Detection of apoptosis
Detection of DNA fragments identifying apoptotic changes was
carried out with an ssDNA apoptosis ELISA kit (Chemicon
International, Temecula, CA, USA) according to the manufacturer’s
instructions. Briefly, this relies upon selective denaturation of DNA
in apoptotic but not necrotic cells, which can be detected by
monoclonal antibody to ssDNA.62
To investigate the effect of BSA on nuclear morphology, PTECs
grown in six-well plates were treated with or without control siRNA
(sc-37007; Santa Cruz Biotechnology) and then exposed to
5 mg ml1 of each of the two sources of BSA for 72 h. Adherent
cells were washed with phosphate-buffered saline, fixed by incuba-
tion with 3% paraformaldehyde for 30 min, washed three times with
phosphate-buffered saline, and stained with Hoechst 33258 (Sigma-
Aldrich) for 20 min. A fragmented nucleus was considered represen-
tative of apoptosis under a fluorescence microscope using standard
excitation filters. The percentage of apoptotic cells was determined
by counting the number of these cells in three randomly selected
high-power fields.
Preparation of cytoplasmic extracts and western blot analysis
Cytoplasmic extracts from PTECs were collected and subjected
to western blotting using previously described methods.22,29 Equal
amounts of protein (30mg) as determined by BCA Protein Assay
(Pierce, Rockford, IL, USA) or volumes of culture supernatants were
subjected to SDS-PAGE and electrophoretically transferred to a
polyvinylidine difluoride membrane (Millipore, Bedford, MA,
USA). Goat Abs to clusterin and NF-kB p65 and cytochrome c
were diluted 1:500, whereas rabbit Abs to IkBa, phospho-p38, p38,
ERK2, Bax, and Bcl-xL and mouse monoclonal antibodies to
phospho-ERK1/2, JNK, and a-tubulin were diluted 1:200 for use in
western blot analysis (all Abs were from Santa Cruz). Reactivity was
detected using the SuperSignal West Dura Extended Duration
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Substrate Kit (Pierce) with intensities quantified densitometrically
(Scion Image, Scion Corporation, Frederick, MD, USA), normal-
ized, and expressed as ratios of the control in each experiment.
Preparation of nuclear extracts and electrophoretic mobility
shift assay
Nuclear extracts were isolated and examined for NF-kB and AP-1
DNA-binding activity as described previously.22 The sequences of
the consensus double-stranded oligonucleotides used to detect
DNA-binding sites were 50-AGTTGAGGGGACTTTCCCAGGC-30
for NF-kB and 50-CGCTTGATGACTCAGCCGGAA-30 for AP-1
(Santa Cruz). The sequences of the mutant oligonucleotides used in
competition assays were 50-AGTTGAGGCGACTTTCCCAGGC-30
for NF-kB and 50-CGCTTGATGACTTGGCCGGAA-30 for AP-1
(Santa Cruz). Consensus oligonucleotides biotinylated with a 30-end
DNA-labeling kit (Pierce) were incubated with 5mg nuclear extracts
and reaction solutions for 30 min on ice. The binding reactions were
separated on a 6% polyacrylamide gel and subsequently electro-
phoretically transferred to a nylon membrane. Biotinylated DNA
was detected with streptavidin–horseradish peroxidase conjugate
and chemiluminescent substrate (Lightshift Chemiluminescent
EMSA Kit, Pierce). As controls, competition reactions were per-
formed in parallel using 20-fold excess unlabeled consensus as well
as mutant oligonucleotide competitors, confirming the specificity of
DNA–protein binding in every experiment.
Statistical analysis
All data are expressed as means7s.e.m. and were analyzed by
analysis of variance. When statistical significance was identified
(Po0.05), comparisons within groups were made by Fisher’s
testing.
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